A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

NCT01456325 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

494

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Onartuzumab (MetMab)
DRUG: Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]